The narcolepsy treatment market is projected to grow from USD 5,301.6 million in 2024 to USD 8,718.3 million by 2034, at a ...

Orexin-Based Therapies: Research is ongoing into nonpeptide orexin receptor agonists, which may provide new treatment options by addressing the underlying hypocretin deficiency seen in narcolepsy.

People who live with narcolepsy — about one out of every 2,000 Americans — don’t have many options when it comes to treatment. The milder form of narcolepsy includes symptoms of excessive ...

Jazz Pharmaceuticals plc recently disclosed its financial update and corporate overview at the J.P. Morgan Healthcare ...

Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda ...

Narcolepsy Treatment Market Narcolepsy Treatment Global Narcolepsy Treatment Market to Grow at 5.1% CAGR, Reaching USD 8,718.3 Million by 2034. Key Drivers Include Advanced Drugs, Devices, & Gro ...

Axsome's drug was given a breakthrough designation from the FDA, reflecting the need for new treatment options in patients ... is AXS-12 (reboxetine) for narcolepsy, which could be filed in ...

We've never been closer to accurately assessing whether an individual is more susceptible to developing major depressive ...

The FDA approves AVDL's Lumryz for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged seven years and older with narcolepsy. -- LUMRYZ is the only FDA-approved once ...

Although low blood pressure (otherwise known as hypotension) rarely requires treatment, it may need so if there are symptoms like severe dizziness or fainting. The treatment varies by the cause and ...